难治性重度抑郁症患者突触增强和氯胺酮快速抗抑郁反应：一项复制研究。
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
机构信息
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.
Abstract
Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min and Day 1 in ketamine responders versus non-responders in 31 depressed subjects and 25 healthy controls. A significant difference in peak gamma power was seen in the depressed ketamine responders versus non-responders. These results implicate AMPA throughput in ketamine's mechanism of antidepressant action.
摘要
临床前和临床证据表明氯胺酮具有快速抗抑郁作用。使用 AMPA 抑制剂预处理的研究表明，增强 AMPA 通透性对于氯胺酮的作用至关重要，包括增加基础和诱发γ波的功率。本研究旨在复制先前的研究结果，即在 31 名抑郁患者和 25 名健康对照者中，氯胺酮反应者与非反应者在 230 分钟和第 1 天对躯体感觉刺激的γ反应增加。在抑郁的氯胺酮反应者与非反应者之间观察到峰值γ功率的显著差异。这些结果表明 AMPA 通透性参与了氯胺酮的抗抑郁作用机制。
相似文献
1
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.
2
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
Biol Psychiatry. 2012 Oct 1;72(7):555-61. doi: 10.1016/j.biopsych.2012.03.029. Epub 2012 Apr 21.
3
Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.
Pharmacol Biochem Behav. 2020 Feb;189:172856. doi: 10.1016/j.pbb.2020.172856. Epub 2020 Jan 17.
4
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Mol Psychiatry. 2019 Jul;24(7):1040-1052. doi: 10.1038/s41380-018-0028-2. Epub 2018 Feb 27.
5
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu039. doi: 10.1093/ijnp/pyu039.
6
Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20.
7
Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
J Psychiatr Res. 2017 Jan;84:113-118. doi: 10.1016/j.jpsychires.2016.09.025. Epub 2016 Sep 30.
8
Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.
Psychopharmacology (Berl). 2018 Oct;235(10):3017-3030. doi: 10.1007/s00213-018-4992-7. Epub 2018 Aug 16.
9
Ketamine: The final frontier or another depressing end?
Behav Brain Res. 2020 Apr 6;383:112508. doi: 10.1016/j.bbr.2020.112508. Epub 2020 Feb 1.
10
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10.
引用本文的文献
1
Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome.
Transl Psychiatry. 2024 Jul 25;14(1):307. doi: 10.1038/s41398-024-03005-8.
2
Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment.
Front Neurosci. 2024 Jun 20;18:1389096. doi: 10.3389/fnins.2024.1389096. eCollection 2024.
3
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.
Proc Natl Acad Sci U S A. 2023 Dec 5;120(49):e2305772120. doi: 10.1073/pnas.2305772120. Epub 2023 Nov 27.
4
Mechanisms of Sustained Increases in Power Post-Ketamine in a Computational Model of the Hippocampal CA3: Implications for Ketamine's Antidepressant Mechanism of Action.
Brain Sci. 2023 Nov 7;13(11):1562. doi: 10.3390/brainsci13111562.
5
Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.
Lancet Psychiatry. 2023 Oct;10(10):790-800. doi: 10.1016/S2215-0366(23)00183-9. Epub 2023 Aug 22.
6
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.
Neuropsychopharmacology. 2024 Jan;49(1):41-50. doi: 10.1038/s41386-023-01629-w. Epub 2023 Jul 24.
7
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Neuropsychopharmacology. 2023 Oct;48(11):1586-1593. doi: 10.1038/s41386-023-01586-4. Epub 2023 Apr 19.
8
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.
Neuropharmacology. 2023 Mar 15;226:109422. doi: 10.1016/j.neuropharm.2023.109422. Epub 2023 Jan 13.
9
Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression.
J Affect Disord. 2022 Sep 1;312:188-197. doi: 10.1016/j.jad.2022.06.025. Epub 2022 Jun 18.
10
Transcriptional Activation, Deactivation and Rebound Patterns in Cortex, Hippocampus and Amygdala in Response to Ketamine Infusion in Rats.
Front Mol Neurosci. 2022 May 30;15:892345. doi: 10.3389/fnmol.2022.892345. eCollection 2022.
本文引用的文献
1
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
Mol Psychiatry. 2019 Jul;24(7):1040-1052. doi: 10.1038/s41380-018-0028-2. Epub 2018 Feb 27.
2
The effects of AMPA blockade on the spectral profile of human early visual cortex recordings studied with non-invasive MEG.
Cortex. 2016 Aug;81:266-75. doi: 10.1016/j.cortex.2016.03.004. Epub 2016 Mar 31.
3
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Nature. 2016 May 26;533(7604):481-6. doi: 10.1038/nature17998. Epub 2016 May 4.
4
Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
Biol Psychiatry. 2012 Oct 1;72(7):555-61. doi: 10.1016/j.biopsych.2012.03.029. Epub 2012 Apr 21.
5
Synaptic AMPA receptor plasticity and behavior.
Neuron. 2009 Feb 12;61(3):340-50. doi: 10.1016/j.neuron.2009.01.015.
6
A new depression scale designed to be sensitive to change.
Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
Zotero 插件